Regnum Corp. (RGMP)
- Previous Close
0.0059 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.4990 - Volume
600 - Avg. Volume
0 - Market Cap (intraday)
2,295 - Beta (5Y Monthly) 2.80
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Recent News: RGMP
Performance Overview: RGMP
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGMP
Valuation Measures
Market Cap
2.29k
Enterprise Value
1.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.74
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.02%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-693.71k
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
462.37k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-687.5k